Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

RCT (n=313) found that when administered alongside standard care, anti-influenza hyperimmune intravenous immunoglobulin was not superior to placebo for clinical status at day 7 in adults hospitalised with influenza infection.

Source: Current Awareness Service for Health (CASH) - October 3, 2019 Category: Consumer Health News Source Type: news